live attenuated varicella vaccine / Sinovac - LARVOL DELTA

Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion) (clinicaltrials.gov) - P4 | N=899 | Completed | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.

New P4 trial • Infectious Disease • Influenza • Respiratory Diseases • Varicella Zoster

Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine (clinicaltrials.gov) - P4 | N=720 | Not yet recruiting | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.

New P4 trial • Infectious Disease • Varicella Zoster

An Immunity Persistence Study of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - P4 | N=703 | Enrolling by invitation | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. | Trial completion date: Dec 2024 ➔ Oct 2025

Trial completion date • Varicella Zoster

PRO-VZV-4005: An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - P4 | N=414 | Enrolling by invitation | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation | Trial completion date: Sep 2028 ➔ Dec 2031 | Trial primary completion date: Sep 2026 ➔ Dec 2028

Enrollment open • Trial completion date • Trial primary completion date • Varicella Zoster

An Immunity Persistence Study of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - P4 | N=703 | Enrolling by invitation | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. | Trial completion date: Jul 2024 ➔ Dec 2024

Trial completion date • Varicella Zoster

An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - P4 | N=414 | Not yet recruiting | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.

New P4 trial • Varicella Zoster

An Immunity Persistence Study of Live Attenuated Varicella Vaccine (clinicaltrials.gov) - P4 | N=703 | Enrolling by invitation | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation | Trial completion date: Jul 2022 ➔ Jul 2024

Enrollment open • Trial completion date • Varicella Zoster

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old (clinicaltrials.gov) - P3 | N=2400 | Enrolling by invitation | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. | Active, not recruiting ➔ Enrolling by invitation

Enrollment open • Varicella Zoster

Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study. (PubMed, Vaccine) - "VarV, manufactured by Sinovac (Dalian), demonstrated higher immune response and better flexibility in the immunization schedule among heathy population aged 13 years and older, without increased safety risk."

Clinical • Journal • Herpes Zoster • Varicella Zoster

Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus (clinicaltrials.gov) - P4 | N=37920 | Recruiting | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Oct 2022 ➔ Mar 2023

Enrollment open • Trial primary completion date • Herpes Zoster • Varicella Zoster

Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province (clinicaltrials.gov) - P4 | N=45400 | Active, not recruiting | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Varicella Zoster

Immunogenicity and safety of a live attenuated varicella vaccine co-administered with inactive hepatitis A vaccine: A phase 4, single-center, randomized, controlled trial. (PubMed, Hum Vaccin Immunother) - P4 | "The incidence rate of adverse reactions in Group A was lower than Group B (9.33% vs 16.22%), and only one serious adverse event was reported in Group B, which was unrelated to the study vaccine. In conclusion, the co-administration of VarV with HepA has non-inferior immunogenicity and safety profiles were quite comparable with the separate administration of both vaccines.Trial registration number: NCT05526820 (ClinicalTrials.gov)."

Journal • P4 data • Hepatology • Herpes Zoster • Infectious Disease • Inflammation • Varicella Zoster

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old (clinicaltrials.gov) - P3 | N=2400 | Active, not recruiting | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd. | Recruiting ➔ Active, not recruiting | Phase classification: P4 ➔ P3 | Trial completion date: Dec 2022 ➔ Sep 2026 | Trial primary completion date: Jul 2022 ➔ Feb 2022

Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Varicella Zoster

A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine (clinicaltrials.gov) - P4 | N=450 | Completed | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.

New P4 trial • Hepatology • Infectious Disease • Inflammation • Varicella Zoster

Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province (clinicaltrials.gov) - P4 | N=45400 | Recruiting | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.

New P4 trial • Varicella Zoster

Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus (clinicaltrials.gov) - P4 | N=37920 | Not yet recruiting | Sponsor: Sinovac (Dalian) Vaccine Technology Co., Ltd.

New P4 trial • Herpes Zoster • Varicella Zoster